Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AVADEL PHARMACEUTICALS PLC Director's Dealing 2018

Mar 2, 2018

31920_dirs_2018-03-02_d6653127-763f-4afc-9327-ba59ae6e8658.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2017-06-28

Reporting Person: VAN ASSCHE BENOIT (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-06-28 Stock Option (right to buy) $10.51 A 35000 Acquired 2022-06-28 ADSs (35000) Direct

Footnotes

F1: Options become exercisable as to all 35,000 ADSs on the first anniversary of the 06/28/2017 grant date.

F2: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.